27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Dublin, May 24, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Crohn's Disease Market and Forecast Analysis" report to their offering.
Crohn's disease involves inflammation of the gastrointestinal (GI) tract and most commonly affects the terminal ileum or colon. Because Crohn's disease can occur in various areas of the GI tract, disease activity and severity can vary widely over time, with symptoms ranging from mild to severe and depending on the location in the GI tract at which the disease is active. Crohn's disease is a chronic, incurable disease with low mortality that is generally diagnosed in adolescence and early adulthood.
Crohn's disease is currently an idiopathic condition, the pathogenesis of which is yet to be fully elucidated. However, it is known to involve an interaction between genetics, the immune system, and environmental factors. Risk factors include ethnicity, smoking, family history, antibiotic or non-steroidal anti-inflammatory agent use, and diet.
It is estimated that in 2015, there were 1.4 million diagnosed prevalent cases of Crohn's disease in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK). Over 2015-35, the number of prevalent cases is expected to increase by 16.9% to 1.6 million.
Key Topics Covered:
1. Treatment: Crohn's Disease
- Executive Summary
- Primary Research Methodology
- Patient Segmentation
- Current Treatment Options
- Prescribing Trends
- Compliance
- Unmet Needs in Crohn's Disease
- Prescribing Influences
- Impact of Biosimilars
2. Epidemiology: Crohn's Disease
- Executive Summary
- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations
3. Marketed Drugs: Crohn's Disease
- Executive Summary
- Product Overview
- Product profile: Cimzia
- Product profile: Entyvio
- Product profile: Humira
- Product profile: Pentasa
- Product profile: Remicade
- Product profile: Tysabri
4. Pipeline: Crohn's Disease
- Executive Summary
- Clinical Pipeline Overview
For more information about this report visit http://www.researchandmarkets.com/research/q5tnsr/crohns_disease
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Immune Disorders Drugs
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!